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Summary
Objective: To obtain descriptive safety and efficacy data for long-term levetiracetam
therapy and to allow patients benefiting from add-on levetiracetam to continue
treatment until the drug was available commercially.
Methods: This long-term, noncomparative, open-label, follow-up study was con-
ducted at 36 US sites. Patients with refractory partial epileptic seizures were eligible
if they had benefited from add-on levetiracetam therapy in a previous study and
wished to continue treatment. The levetiracetam dose was individualized over the
range of 1000—4000 mg/day. Withdrawal of concomitant AEDs to allow levetiracetam
monotherapy was permitted. Patients were evaluated every 12 weeks and followed
for up to 4 years. Median total seizure frequency per week was the primary efficacy
variable.
Results: A total of 280 subjects, most of whom had refractory partial seizures with or
without secondary generalization, were evaluated. Most were receiving either one
(34.6%) or two (53.2%) concomitant antiepileptic drugs (AEDs) at entry. Overall, 199
(71.1%) subjects completed the study and 81 (28.9%) withdrew prematurely, most
commonly due to loss or lack of efficacy or adverse events. The median total seizure
frequency per week (0.7 at the selection visit) remained stable. The probability of
being seizure-free during the first 12 weeks was 13.4% and 3.7% by week 216. Twenty-
five (8.9%) subjects received levetiracetam monotherapy for at least 100 days.
Levetiracetam was safe and well tolerated; the most common levetiracetam-related
adverse events were dizziness (6.8%), convulsion (5.7%), and somnolence (5.0%).
Conclusion: Efficacy and safety were maintained during long-term levetiracetam
treatment of refractory partial seizures.
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Levetiracetam (Keppra1, UCB S.A.) is a novel anti-
epileptic drug (AED) that is indicated as adjunct
therapy of partial-onset seizures in adults with epi-
lepsy.1,2 The efficacy and safety of levetiracetam has
been demonstrated in a series of clinical studies. In
the three pivotal trials, add-on levetiracetam was
significantly more effective than placebo in reducing
seizure frequency in patients with refractory partial
seizures.3—5 In these studies, levetiracetam was
initiatedat adoseof 1000 mg/dayand then increased
to 2000 mg/day or 3000 mg/day given in two divided
doses. In a fourth study that focused principally on
safety and tolerability, levetiracetamwas initiatedat
daily doses of 2000 mgor 4000 mgwithout titration in
patients with refractory epilepsy of any type.6 Treat-
ment was well tolerated and again shown to be
significantly more effective than placebo. The
4000-mg dose (but not 2000-mg dose) was associated
with an increased incidence of somnolence, but this
did not lead to more discontinuations.
Investigators have continued to follow patients
who participated in these short-term clinical trials
to assess long-term efficacy and tolerability. Patients
who completed the pivotal placebo-controlled trial
conducted in the United States (study N132)4 and
wished to continue (or switch from placebo to) leve-
tiracetam therapy were eligible to enroll in a 54-
week open-label follow-up study (study N140). After
completion of study N140, patients were eligible to
enroll in the long-term follow-up study reported
herein. Also eligible for the present study were
patients with refractory epilepsy who completed a
12—16-weekopen-label trial ofadd-on levetiracetam
(studyN153),7 andpatientswith partial and/or tonic-
clonic seizures not fully controlled by monotherapy
with maximum tolerated doses of phenytoin who
completed a small 29-week open-label trial of leve-
tiracetam as add-on treatment (study N143).
The objectives of the current study were to
obtain descriptive safety and efficacy data for
patients receiving long-term levetiracetam therapy
at individualized doses of 1000—4000 mg/day, and
to allow patients who had benefited from levetir-
acetam to continue with their treatment until the
drug became available commercially.
Methods
Study design
This long-term, noncomparative, open-label, fol-
low-up study was conducted at 36 US sites. Patients
with partial epileptic seizures who had participatedin a previous study of add-on levetiracetam therapy
continued to receive levetiracetam and their exist-
ing AED therapy, if required, until the drug received
marketing approval in the US and became available
commercially. Duration of exposure varied, there-
fore, depending on the enrollment date. Subjects
were evaluated every 12 weeks. At the investiga-
tors’ discretion, the dose of levetiracetam was
adjusted over the range of 1000—4000 mg/day to
individualize therapy. Tapering and then withdrawal
of concomitant AEDs was permitted to allow leve-
tiracetam monotherapy.
This study was conducted according to the prin-
ciples of the Declaration of Helsinki, and in accor-
dance with Good Clinical Practices and applicable
federal regulations. The protocol and statement of
informed consent were approved by the Institu-
tional Review Board at each study site.
Patients
Patients with epileptic seizures who completed a
previous levetiracetam study (N132 and N140, N143,
or N153) were eligible for the present study if they
benefited from levetiracetam and wished to con-
tinue therapy. Most subjects (n = 183) had partial-
onset seizures with or without secondary general-
ization and entered this study after first completing
a 38-week, double-blind, placebo-controlled, par-
allel-group study (N132) and then a 54-week, open-
label, follow-up study (N140). One subject entered
directly after completing study N132. Ninety sub-
jects with refractory epilepsy (partial or general-
ized) entered after completing a 12—16-week,
open-label, multicenter study (N153), and six
patients with partial and/or tonic-clonic seizures
not fully controlled by maximum tolerated doses of
phenytoin monotherapy entered after completing a
29-week, open-label interaction study (N143).
A total of 37 patients in study N153 had general-
ized epilepsy during the evaluation period of that
study. Only US patients from N153 could be enrolled
into the present study. Therefore, it is possible that
a subset of US patients from the 37 patients in N153
enrolled in the present study. Fourteen patients
experienced at least one generalized seizure during
their participation in the current study. One hun-
dred and seventy-two of the 179 patients who com-
pleted participation in study N153 entered a long-
term follow-up study, with 90 patients entering the
present study (the long-term study conducted in the
US) and 82 patients entering study N129 (the long-
term follow-up study conducted in Europe).
All subjects provided written informed consent
before participating. For those under 18 years of
age, the consent of both the patient and parent or
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potential were required to use a medically accep-
table method of birth control.
Subjects were excluded from the present study if
they had a significant psychiatric disturbance, his-
tory of drug or alcohol abuse, rapidly progressive
neurological disorder or cerebral tumor, degenera-
tive cerebral disease, cerebrovascular accident,
other clinically significant disease, leukopenia, or
impaired renal or hepatic function. Patients with a
history of severe allergic reactions or poor compli-
ance to a study schedule or drug intake were also
excluded, as were those participating in another
ongoing clinical study and women who were preg-
nant or lactating. Drugs with central nervous system
effects, such as neuroleptics, antidepressants,
anxiolytics, psychostimulants, anticholinergics,
tranquilizers, hypnotics, and narcotic analgesics,
were not allowed.
Up to three concomitant AEDs were allowed.
Treatment was discontinued when a subject with-
drew consent, failed to comply with the protocol or
drug treatment schedule, or became pregnant, or if
in the investigator’s opinion, it was warranted by an
adverse event or by loss or lack of efficacy. To
measure drug compliance, the number of tablets
dispensed and returned was recorded in the case
report form and dispensing log. The intake of study
drug was required to be within 80—120% of the
prescribed dose.
Selection and timing of doses
Levetiracetam was to be administered in two equal
doses, once in the morning and once in the evening.
The dose was continued from the previous study and
then individualized at the discretion of the investi-
gator. A daily dose of 4000 mgwas initially allowed in
the protocol, but an amendment to the protocol
permitted this dose only if a careful review showed
that the subject tolerated a 3000-mg dose during
treatment for approximately 12 weeks, and the sei-
zure frequency during levetiracetam therapy showed
a trend that, in the investigator’s judgment, sug-
gested a dose increase above 3000 mg would benefit
the patient. If the subject or investigator decided to
discontinue levetiracetam, the drug was withdrawn
gradually over a 2—8-week period. The schedule for
withdrawal was defined by the investigator for each
individual subject, with a step-down of up to 500 mg
per week recommended in the protocol.
Concomitant AED therapy
Up to three concomitant AEDs from the following list
were allowed: carbamazepine, ethotoin, topira-mate, phenytoin, valproic acid, phenobarbital, pri-
midone, clonazepam, ethosuximide, methsuximide,
gabapentin, lamotrigine, and acetazolamide. Tia-
gabine was not permitted, because a commercial
assay was not available when the study was started.
Benzodiazepines used occasionally for seizure con-
trol were recorded as AEDs. The dose of the con-
comitant AEDs was to remain unchanged throughout
the study, unless the investigator was obliged by
circumstances of safety or efficacy to adjust the
dose. If an investigator chose to substitute one
concomitant AED for another, the ineffective AED
was tapered and the new AED was uptitrated, most
often simultaneously. In such cases, the substitution
of one AED for another was considered to represent
one concomitant AED. At any time during the study,
the investigator could withdraw the concomitant
AED to allow levetiracetam monotherapy.
Safety variables
Clinic visits were scheduled at 12-week intervals. At
each visit, complete physical and neurological
examinations as well as laboratory assessments,
including hematology, blood chemistry, urine ana-
lysis, and plasma levels of levetiracetam and con-
comitant AEDs, were conducted. A serum
pregnancy test was performed for all women, with
the exception of thosewhowere postmenopausal or
surgically sterilized. Adverse events were identi-
fied from spontaneous reporting by the patient,
clinical observations by the investigator, and ques-
tioning of the patient about their health. The nat-
ure and severity of all adverse events and their
causal relationship to study drug were recorded
by the investigator. Adverse events were then clas-
sified according to the Coding Symbols for The-
saurus of Adverse Reaction Terms (COSTART)
dictionary.8 A standard 12-lead electrocardiogram
(ECG)was performedevery 48weeks and at the final
study visit.
Efficacy variables
Subjects recorded the date, number, duration, and a
description of all seizures on daily record cards. At
each clinic visit, investigators reviewed the record
cards and coded all seizures according to the Inter-
national Classification of Epileptic Seizures.9 The
primary efficacy variable was defined as the median
total seizure frequency per week. This measure
included the sum of partial (type I), generalized
(type II), and unclassifiable (type III) seizures. Sec-
ondary efficacy variables were the median partial
seizure frequency per week and the occurrence of
seizure-free intervals.
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Subjects who received at least one dose of levetir-
acetam were included in the intent-to-treat popu-
lation. Due to the open-label design of this study,
the efficacy and safety data were evaluated primar-
ily using descriptive statistics. The total and partial
seizure frequencies were calculated for each 12-
week interval and for the entire duration each
patient remained in the study. Because some sub-
jects had much higher seizure frequency as com-
pared to the majority of subjects, the median
seizure frequency per week was used to summarize
the data for the study population. A life-table sur-
vival analysis was used to estimate the probability of
being continuously seizure-free for a specified time
interval in two different ways. The first analysis was
very conservative and focused on how long a patient
who achieved seizure freedom at the start of the
study remained seizure-free. As a consequence,
subjects who had at least one seizure in the first
3 months of the study were considered to be fail-
ures, even if they became seizure-free later on. The
second analysis was less restrictive and evaluated
the duration of seizure-free periods that started at
any time during the study. In this analysis, if subjects
hadmultiple seizure-free periods, the last one (even
if not the longest one) was selected.
Safety data were summarized descriptively over
6-month intervals. For adverse events, the numberFigure 1 Disposition of subjects. Patients entered the study
therapy. *N153 was a global study and only US patients wereand percentage of patients was tabulated by body
system, COSTART preferred term, severity, and rela-
tionship to treatment.
Results
Patient disposition and demographics
A total of 281 subjects enrolled in this study after
completing a previous study of add-on levetirace-
tam therapy (Fig. 1). All were included in the intent-
to-treat population, except one patient who
recorded few data points in the daily record card
and was considered to be unreliable by the investi-
gator. Of the remaining 280 patients, 199 (71.1%)
subjects completed the study and 81 (28.9%) termi-
nated the study prematurely. The most common
reasons for premature termination were loss or lack
of efficacy, adverse events, and withdrawn consent
(Fig. 1).
The study population ranged in age from 17.7
years to 72.5 years, with most being male and white
(Table 1). Three (1.1%) patients were aged 65 years
or older. The etiology of epilepsy was unknown in
114 (40.7%) subjects, whereas it was caused by
cranial trauma in 57 (20.4%) subjects and other
factors in 59 (21.1%) subjects. Etiologies including
asphyxia during birth, cerebral infection, congenital
malformation, and genetic origin were reported byafter completing a previous study of add-on levetiracetam
eligible for enrollment.
Levetiracetam for partial seizures 581
Table 1 Patient demographics and clinical character-
istics.
Characteristic Levetiracetam
(N = 280)
Age (years), mean  S.D. 40  11
Weight (kg), mean  S.D. 80.2  19.3a
Body mass index (kg/m2),
mean  S.D.
27.4  6.2b
Gender, n (%)
Male 170 (60.7)
Female 110 (39.3)
Race, n (%)
White 245 (87.5)
Black 22 (7.9)
Asian 1 (0.4)
Other 12 (4.3)
Age at onset of epilepsy (years),
mean  S.D.
14.8  12.1
Duration of epilepsy (years),
mean  S.D.
25.4  12.2
Seizure frequency per week,
median (Q1—Q3)
Total 0.7 (0.2—1.9)
Partial-onset 0.7 (0—1.9)
Concomitant AEDs at selection visit, n (%)
0 11 (3.9)
1 97 (34.6)
2 149 (53.2)
3 23 (8.2)
a n = 277 because of missing data.
b n = 274 because of missing data.fewer than 8% of subjects. The following etiologies
were also reported by a few patients: brain surgery,
cerebral neoplasm, cerebrovascular accident, com-
plications due to prematurity, and intrauterine viral
infection. The mean age at epilepsy onset was 14.8
years, and the mean duration of epilepsy was 25.4
years. Because the vast majority of patients enter-
ing this study had partial-onset seizures with or
without generalization, the median total and partial
seizure frequency at the selection visit (computed
on the 4-week period prior to selection) were simi-
lar–—both were 0.7 per week.
Most patients were receiving either one (97 sub-
jects, 34.6%) or two (149 subjects, 53.2%) concomi-
tant AEDs when they entered this study (Table 1).
Eleven (3.9%) subjects were receiving levetiracetam
monotherapy. The most common concomitant AEDs
were carbamazepine (131 subjects, 47.1%), lamo-
trigine (103 subjects, 36.8%), phenytoin (97 sub-
jects, 34.6%), gabapentin (72 subjects, 25.7%),
topiramate (59 subjects, 21.1%), and valproic acid
and derivatives (56 subjects, 20.0%). By the end of
the study period, the number of patients receivinglevetiracetam monotherapy had increased to 25
(8.9%), but most were still receiving either one
(93 subjects, 33.2%) or two (133 subjects, 47.5%)
concomitant AEDs.
Mean treatment compliance during the entire
evaluation period was 98.4%. Most patients
(97.9%) had a compliance of between 80% and 120%.
Efficacy
Seizure frequency
The median total seizure frequency per week and
the median partial-onset seizure frequency per
week, both 0.7 at the selection visit, remained
stable throughout the evaluation period (Fig. 2).
In the period between 2 years and 3.5 years, when
about half of the study population was still available
for analysis, the median total seizure frequency per
week was 0.4—0.5, and the median partial-onset
seizure frequency per week was 0.4. The observa-
tions for the 2—3.5-year period should be considered
in the context of the decreased study population.
Subsets of patients with common minimal dura-
tions of exposure were also considered. The median
total seizure frequency per week ranged from 0.6 to
0.7, 0.5 to 0.7, and 0.4 to 0.7, respectively, in
evaluable patients treated for at least 1 year (225
subjects, 80.4%), 2 years (136 subjects, 48.6%), or 3
years (128 subjects, 45.7%). Similarly, the median
partial-onset seizure frequency per week remained
stable. It ranged from 0.6 to 0.7, 0.5 to 0.6, and 0.4
to 0.6 in subjects treated for at least 1 year (225
subjects, 80.4%), 2 years (136 subjects, 48.6%), or 3
years (128 subjects, 45.7%).
Seizure freedom
Seizure freedom was first determined for each sub-
ject from his or her enrollment in this study. The
percentage of subjects who were continuously sei-
zure-free during the first 12-week evaluation period
was 13.4%. Thereafter, the cumulative percentage
of seizure-free subjects gradually declined to 8.7%
by week 48, 5.7% by week 108, 5.1% by week 168,
and 3.7% by week 216. Duration of seizure freedom
at any time during the study was also investigated
(using the last seizure-free period of each subject if
multiple periods existed). The probability of being
seizure-free for at least 12 weeks was 29.5% and
gradually decreased to 13.7% for at least 216 weeks.
Levetiracetam monotherapy
A total of 34 (12.1%) subjects received levetirace-
tam monotherapy for one or more intervals of at
least 30 days, including the 11 patients who had
entered the study on levetiracetam monotherapy.
Nine (3.2%) subjects received monotherapy for 30—
582 B. Abou-Khalil, L. Schaich
Figure 2 Median total and partial-onset seizure frequencies per week over the evaluation period by cumulative
duration of exposure (intent-to-treat population).100 days, seven (2.5%) for 101—365 days, seven
(2.5%) for 1—2 years, and 11 (3.9%) for more than
2 years. Among the 25 subjects who received leve-
tiracetam monotherapy for more than 100 days,
most were started at a daily dose of 3000 mg (16
subjects, 64%) or 4000 mg (five subjects, 25%). The
other four patients started levetiracetam mono-
therapy at doses of 1000—2500 mg. Data were not
collected to allow a meaningful analysis of any
changes in seizure type, frequency, or duration in
these patients.
Safety
The study population received levetiracetam for a
median of 670 days (range, 65—1469 days). Overall,
128 (45.7%) subjects were treated for more than 3years, nine (3.2%) for >2 to 3 years, 91 (32.5%) for
>1 to 2 years, and 52 (18.6%) for up to 1 year.
A total of 275 (98.2%) of the 280 subjects experi-
enced at least one study-emergent adverse event
(Table 2). The most common events (>20%) were
accidental injury, infection, pain, headache, flu syn-
drome, convulsion, and dizziness, and for each of
these, the investigator considered themajority to be
unrelated to levetiracetam therapy. Despite the high
incidence of infection and flu syndrome, none of
these events was considered to be related to levetir-
acetam. Levetiracetam-related adverse events were
reported for nearly half (131 subjects; 46.8%) of the
study population. The highest incidence of such
adverse events occurred in the nervous system (87
subjects, 31.1%), body as a whole (35 subjects,
12.5%), and digestive system (23 subjects, 8.2%).
Only three levetiracetam-related adverse events
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Table 2 Most frequently reported study-emergent adverse events (5% for levetiracetam-related events).
All adverse events n (%) Levetiracetam-relateda n (%)
One or more adverse event 275 (98.2) 131 (46.8)
Serious adverse event 71 (25.4) 9 (3.2)
Accidental injury 132 (47.1) 6 (2.1)
Infection 127 (45.4) 0
Pain 80 (28.6) 3 (1.1)
Headache 78 (27.9) 10 (3.6)
Flu syndrome 61 (21.8) 0
Convulsion 60 (21.4) 16 (5.7)
Dizziness 60 (21.4) 19 (6.8)
Somnolence 33 (11.8) 14 (5.0)
a Based on investigator judgment.occurredat an incidence of 5%or higher: dizziness (19
subjects, 6.8%), convulsion (16 subjects, 5.7%), and
somnolence (14 subjects, 5.0%).
Serious adverse events were reported for 71
(25.4%) subjects during the evaluation period. The
most common were convulsion (22 subjects, 7.9%),
therapeutic procedure for epilepsy (11 subjects,
3.9%), accidental injury (eight subjects, 2.9%),
and diagnostic procedure for epilepsy (six subjects,
2.1%). In nine subjects (3.2%), serious adverse
events were considered to be related to study treat-
ment.
Overall, 44 subjects (15.7%) experienced adverse
events that led to a reduction in the total daily dose
of levetiracetam or to withdrawal from the study;
this reflects the development of any adverse event,
not study-emergent events. A total of 20 patients
(7.1%) discontinued treatment because of adverse
events. These 20 included five subjects who died
during the course of the study (two from myocardial
infarction, one from metastatic ovarian cancer, one
from sudden unexpected death in epilepsy, and the
other from undetermined causes, possibly arrhyth-
mia). All deaths were considered by the investigator
to be unrelated to study treatment. Only three
patients exited because of behavioral adverse
experiences: one because of an aggressive reaction,
one because of irritability, and one because of an
intentional overdose.
The results of physical and neurological examina-
tions as well as measurement of vital signs and ECG
did not suggest any clinically meaningful changes
over the course of the study. Laboratory parameters
showed little change during the study, and in most
cases, they remainedwithin normal ranges. Changes
in laboratory parameters of possible clinical signifi-
cance included increases in gamma-glutamyltrans-
ferase (GGT; 18 subjects, 6.4%), decreases in
hematocrit (14 subjects, 5.0%), decreases in neu-
trophil counts and increases in eosinophil counts (11
subjects, 3.9% for each), and decreases in white
blood cell counts (13 subjects, 4.6%). With respectto the changes in GGT, it is important to note that
themajority of subjects were receiving concomitant
AEDs, which are known to induce this kind of
abnormality. Thirteen subjects reported raised
GGT values as adverse events, and of these, two
were recorded as possibly related to study drug.
Discussion
This study was designed to allow patients who had
benefited from levetiracetam therapy to continue
with their treatment until the drug became avail-
able commercially, and to obtain descriptive safety
and efficacy data for patients receiving long-term
treatment at individualized doses of 1000—
4000 mg/day. Many of the patients had participated
in the pivotal US multicenter study of levetiracetam
(study N132) and then in a 54-week, open-label
follow-up (study N140).4 When initially enrolled in
the pivotal US study, these patients had uncon-
trolled partial seizures with or without secondary
generalization for at least 2 years and had received
at least two marketed AEDs either simultaneously or
consecutively. Patients were randomly assigned to
receive levetiracetam 1000 mg/day or 3000 mg/day
or placebo as add-on therapy to one or two con-
comitant AEDs. At baseline, the median partial
seizure frequency per week ranged from 1.8 to
2.5 in the three groups. Both doses of levetiracetam
produced significantly greater median reductions in
partial seizure frequency compared with placebo
(32.5% and 37.1% versus 6.8%, P < 0.001). Moreover,
a significantly greater percentage of patients trea-
ted with levetiracetam responded with at least 50%
and 75% reductions in seizure frequency compared
with placebo. Of the 294 randomized patients, 268
completed the study, 266 chose to continue in the
54-week open-label follow-up study, and 183
entered the present study.
The other major group of patients in the present
study had epilepsy refractory to previous treatment
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16-week open-label trial (study N153).7 In that
study, levetiracetam significantly reduced the med-
ian total seizure frequency from 2.25 at baseline to
1.1 during the evaluation period, with nearly half of
the patients achieving 50% or greater reductions in
seizure frequency. Of the 219 patients allocated to
treatment, 172 who completed the evaluation per-
iod chose to continue adjunctive levetiracetam
therapy, including 90 patients who entered the
present study.
In the current study, treatment with individua-
lized doses of levetiracetam continued to maintain
the seizure control achieved in the previous trials.
At baseline, the median seizure frequency per week
was 0.7 for both total and partial-onset seizures,
consistent with the marked preponderance of
patients with partial-onset seizures in the study
population. The median seizure frequency of the
entire study population appeared to decline over
time, but it is important to recognize that patients
participated in this study for varying durations and
were exposed to levetiracetam for varying lengths
of time. The stability of seizure control with leve-
tiracetam therapy was apparent when the subsets of
patients who participated in the study for at least 1
year, 2 years, and 3 years were evaluated sepa-
rately. For the subset of 128 patients who received
treatment for at least 3 years, the median total
seizure frequency per week was 0.7 at the selection
visit and ranged from 0.4 to 0.7 during the third
year, whereas the median partial seizure frequency
per week was 0.6 at the selection visit and ranged
from 0.4 to 0.7 in the third year. There were no signs
of tolerance to levetiracetam.
The efficacy of levetiracetam was also evaluated
by its ability to provide seizure freedom. This para-
meter was evaluated in two ways–—seizure freedom
from the start of the study, and seizure freedom
lasting for a specific duration during the study. The
probability of remaining seizure-free for the first 12
weeks of the study was 13.4%, which then declined
gradually over time. By 4 years, the probability of
being seizure-free since the beginning of the study
was 3.7%. In the two pivotal studies of levetiracetam
in which a daily dose of 3000 mg was used, approxi-
mately 8.2% of the patients randomized to the 3000-
mg arms were seizure-free during the 12—14-week
evaluation of add-on therapy.3,4 The higher prob-
ability seen during the first 12-week interval of the
present study is likely attributed to the nature of the
patient population, which included those who had
already shown a benefit of add-on levetiracetam
therapy. In the current study, the probability of
having a seizure-free interval of 12 weeks was
29.5%, and the probability of having a seizure-freeinterval of 4 years was 13.7%. This latter analysis,
however, was influenced by the varying lengths of
time that patients participated in the study.
The pivotal trial by Ben-Menachem et al.3 showed
that patients with refractory partial seizures who
responded to levetiracetam with a 50% or greater
reduction in seizure frequency could be successfully
converted to levetiracetam monotherapy. In that
study, 49 of 69 eligible patients were converted
successfully to monotherapy, and this group showed
a median percentage reduction in partial seizure
frequency of 73.8% during monotherapy compared
with baseline. The results of the present study
extend these short-term findings by showing that
some patients can be maintained on long-term
levetiracetam monotherapy. Eleven (3.9%) subjects
entered the current study while receiving levetir-
acetam monotherapy, and overall, 25 (8.9%)
patients received monotherapy for more than 100
days during the study. Eleven (3.9%) subjects
received monotherapy for more than 2 years.
Recently, Ben-Menachem et al.10 reviewed the
data collected for all 1422 patients with refractory
epilepsy treated with levetiracetam for 6—54
months during the development program. Overall,
the number of concomitant AEDs could be reduced
in 205 patients (14.4%), and 79 (5.5%) were taking
levetiracetammonotherapy at the end of follow-up.
It also appeared that long-term adverse events were
similar in nature to those seen with short-term
levetiracetam therapy in the pivotal trials.3—6
Long-term tolerability similar to that seen in the
short-term clinical trials, and sustained efficacy,
have also been reported by Ben-Menachem and
Gilland11 in patients who are generally not eligible
for clinical trials due to factors, such as mental
retardation or concomitant psychiatric disorders.
In a long-term study of patients with refractory
disease, treatment-emergent adverse events are to
be expected. In most cases, however, these adverse
events have been considered unrelated to levetir-
acetam therapy. In the current study, the most
common levetiracetam-related adverse events
were dizziness, ‘‘convulsion’’, and somnolence,
consistent with the previous studies in which these
patients participated4,7 as well as with other con-
trolled clinical trials of add-on levetiracetam.3,5,6 In
general, the incidence of adverse events with leve-
tiracetam in previous studies was unrelated to dose.
Most adverse events appear to develop during up-
titration, suggesting that these events are triggered
by the initial exposure to the drug but lessen over
time.
The physical and neurological examinations,
which were conducted every 12 weeks, did not
reveal any clinically meaningful changes over the
Levetiracetam for partial seizures 585course of the study. In patients with epilepsy, GGT
levels are often elevated. The increase is usually
attributed to the liver enzyme induction seen with
AED therapy. Unlike other AEDs, levetiracetam does
not induce liver enzyme activities.12 Review of the
changes in GGTshowed no correlation with exposure
to levetiracetam, and in most cases, these changes
were transient and improved as levetiracetam
treatment continued.
In summary, the present study demonstrates that
the efficacy and tolerability of add-on levetirace-
tam therapy are maintained during long-term treat-
ment. Patients received individualized doses that
were adjusted based on the clinical judgment of the
investigator. Median seizure frequency remained
stable throughout the 4-year evaluation period,
with some patients being free of seizures for sig-
nificant intervals during the study. Additionally,
some patients were maintained effectively on leve-
tiracetam monotherapy.
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